Kaur J, Dora S (2023) Purinergic signaling: diverse effects and therapeutic potential in cancer. Front Oncol 13:1058371

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36(3):293–303

Article  PubMed  Google Scholar 

Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18(10):601–618

Article  PubMed  Google Scholar 

von Kügelgen I (2021) Molecular pharmacology of P2Y receptor subtypes. Biochem Pharmacol 187:114361

Article  Google Scholar 

Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 3(7):e2599

Article  PubMed  PubMed Central  ADS  Google Scholar 

Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK et al (2002) Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110(7):993–1002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poth JM, Brodsky K, Ehrentraut H, Grenz A, Eltzschig HK (2013) Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease. J Mol Med (Berl) 91(2):183–193

Article  CAS  PubMed  Google Scholar 

Hatfield SM, , Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R et al (2015) Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 7(277):277ra30

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sitkovsky MV, Hatfield S, Abbott R, Belikoff B, Lukashev D, Ohta A (2014) Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res 2(7):598–605

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. N Engl J Med 367(24):2322–2333

Article  CAS  PubMed  PubMed Central  Google Scholar 

Longhi MS, Moss A, Jiang ZG, Robson SC (2017) Purinergic signaling during intestinal inflammation. J Mol Med (Berl) 95(9):915–925

Article  CAS  PubMed  Google Scholar 

Allard B, Longhi MS, Robson SC, Stagg J (2017) The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev 276(1):121–144

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nascimento DC, Viacava PR, Ferreira RG, Damaceno MA, Piñeros AR, Melo PH et al (2021) Sepsis expands a CD39⁺ plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity. Immunity 54(9):2024–41.e8

Article  CAS  PubMed  Google Scholar 

Longhi MS, Vuerich M, Kalbasi A, Kenison JE, Yeste A, Csizmadia E, Vaughn B, Feldbrugge L, Mitsuhashi S, Wegiel B, Otterbein L, Moss A, Quintana FJ, Robson SC (2017) Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. JCI Insight 2(9):e92791. https://doi.org/10.1172/jci.insight.92791

Article  PubMed  PubMed Central  Google Scholar 

Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE et al (2011) CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11(4):367–372

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salvestrini V, Zini R, Rossi L, Gulinelli S, Manfredini R, Bianchi E et al (2012) Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood 119(1):217–226

Article  CAS  PubMed  Google Scholar 

Thapa A, Abdelbaset-Ismail A, Chumak V, Adamiak M, Brzezniakiewicz-Janus K, Ratajczak J et al (2022) Extracellular adenosine (eAdo) - A(2B) receptor axis inhibits in Nlrp3 inflammasome-dependent manner trafficking of hematopoietic stem/progenitor cells. Stem Cell Rev Rep 18(8):2893–2911

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grassi F, De Ponte CB (2021) The P2X7 Receptor in tumor immunity. Front Cell Dev Biol 9:694831

Article  PubMed  PubMed Central  Google Scholar 

He X, Zhang Y, Xu Y, Xie L, Yu Z, Zheng J (2021) Function of the P2X7 receptor in hematopoiesis and leukemogenesis. Exp Hematol 104:40–47

Article  CAS  PubMed  Google Scholar 

Salvestrini V, Orecchioni S, Talarico G, Reggiani F, Mazzetti C, Bertolini F et al (2017) Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget 8(4):5895–5908

Article  PubMed  Google Scholar 

Feng W, Yang F, Wang R, Yang X, Wang L, Chen C et al (2016) High level P2X7-mediated signaling impairs function of hematopoietic stem/progenitor cells. Stem Cell Rev Rep 12(3):305–314

Article  CAS  PubMed  Google Scholar 

Bujko K, Adamiak M, Abdelbaset-Ismail A, Thapa A, Ilowska N, Ratajczak J et al (2022) Novel evidence that the P2X1 purinergic receptor-Nlrp3 inflammasome axis orchestrates optimal trafficking of hematopoietic stem progenitors cells. Folia Histochem Cytobiol 60(3):280–290

Article  CAS  PubMed  Google Scholar 

He X, Xu Y, Huang D, Yu Z, Yu J, Xie L et al (2023) P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways. Leukemia 37(2):265–275

Article  CAS  PubMed  Google Scholar 

Saffioti NA, Alvarez CL, Bazzi Z, Gentilini MV, Gondolesi GE, Schwarzbaum PJ et al (2023) Dynamic recycling of extracellular ATP in human epithelial intestinal cells. PLoS Comput Biol 19(6):e1011196

Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

Lara R, Adinolfi E, Harwood CA, Philpott M, Barden JA, Di Virgilio F et al (2020) P2X7 in cancer: from molecular mechanisms to therapeutics. Front Pharmacol 11:793

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hevia MJ, Castro P, Pinto K, Reyna-Jeldes M, Rodríguez-Tirado F, Robles-Planells C et al (2019) Differential effects of purinergic signaling in gastric cancer-derived cells through P2Y and P2X receptors. Front Pharmacol 10:612

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sak K, Boeynaems JM, Everaus H (2003) Involvement of P2Y receptors in the differentiation of haematopoietic cells. J Leukoc Biol 73(4):442–447

Article  CAS  PubMed  Google Scholar 

Zhou Y, Arredondo HM, Wang N (2021) P2Y Receptors in bone—anabolic, catabolic, or both? Front Endocrinol (Lausanne) 12:818499

Article  PubMed  Google Scholar 

Janho Dit Hreich S, Hofman P, Vouret-Craviari V (2023) The role of IL-18 in P2RX7-mediated antitumor immunity. Int J Mol Sci 24(11):9235. https://doi.org/10.3390/ijms24119235

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E et al (2017) ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells. Front Immunol 8:1918

Article  PubMed  PubMed Central  Google Scholar 

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 15(10):1170–1178

Article  CAS  PubMed  Google Scholar 

Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G et al (2010) Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 70(3):855–858

Article  CAS  PubMed  Google Scholar 

De Salis SKF, Li L, Chen Z, Lam KW, Skarratt KK, Balle T, Fuller SJ (2022) Alternatively Spliced Isoforms of the P2X7 Receptor: Structure, Function and Disease Associations. Int J Mol Sci 23(15):8174. https://doi.org/10.3390/ijms23158174

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chong JH, Zheng GG, Zhu XF, Guo Y, Wang L, Ma CH et al (2010) Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. Biochem Biophys Res Commun 391(1):498–504

Article  CAS  PubMed  Google Scholar